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Dysregulation of Mir-196b in 
Head and Neck Cancers Leads to 
Pleiotropic Effects in the Tumor 
Cells and Surrounding Stromal 
Fibroblasts
Saúl Álvarez-Teijeiro1, Sofía T. Menéndez1, M. Ángeles Villaronga1, Juan P. Rodrigo1, 
Lorea Manterola2, Lucas de Villalaín3, Juan C. de Vicente3, Laura Alonso-Durán1, M. Pilar 
Fernández4, Charles H. Lawrie2,5 & Juana M. García-Pedrero1
The miR-196 family members have been found dysregulated in different cancers. Therefore, they have 
been proposed as promising biomarkers and therapeutic targets. This study is the first to investigate 
the role of miR-196b in the development and progression of head and neck squamous cell carcinomas 
(HNSCC), and also the impact on the surrounding tumor microenvironment. Increased miR-196b levels 
were detected in 95% of primary tumors and precancerous lesions, although no significant differences 
were observed between non-progressing versus progressing dysplasias. Furthermore, increased levels 
of both miR-196a and miR-196b were successfully detected in saliva samples from HNSCC patients. 
The functional consequences of altered miR-196 expression were investigated in both HNSCC cell 
lines and cancer-associated fibroblasts (CAFs) by transfection with specific pre-miR precursors. Results 
showed that both miR-196a and miR-196b elicit cell-specific responses in target genes and downstream 
regulatory pathways, and have a distinctive impact on cell proliferation, migration and invasion. These 
data reveal the early occurrence and prevalence of miR-196b dysregulation in HNSCC tumorigenesis, 
suggesting its utility for early diagnosis and/or disease surveillance and also as a non-invasive biomarker 
in saliva. The pleiotropic effects of miR-196a/b in HNSCC cell subpopulations and surrounding CAFs may 
complicate a possible therapeutic application.
Head and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous disease in terms of etiology, with 
multiple genetic and molecular alterations and varying biologic behavior and clinical outcomes1,2. Therefore 
much work has focused on the identification of biologic and molecular factors that may serve as prognostic and 
predictive markers, as well as new targets for therapy3.
MicroRNAs (miRNAs) have emerged as crucial players4–7 in regulating gene expression in normal homeo-
stasis and also numerous disorders, including autoimmune, cardiovascular and neurodegenerative diseases and 
cancer8–10.
The members of the miR-196 gene family (miR-196a-1, miR-196a-2, and miR-196b) are transcribed from 
three different genes, which are located in homeobox (HOX) gene cluster regions in humans11,12. The mature 
nucleotide sequences of miR-196a-1 of miR-196a-2 are identical, whereas mature miR-196b differs from miR-
196a by one nucleotide12. Numerous studies indicate that the miR-196 family plays critical roles in normal devel-
opment and pathogenesis, and may therefore have great potential in clinical applications such as the diagnosis, 
1Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria 
del Principado de Asturias, IUOPA, University of Oviedo, Oviedo, CIBERONC, Spain. 2Molecular Oncology Group, 
Biodonostia Research Institute, San Sebastián, Spain. 3Department of Oral and Maxillofacial Surgery, Hospital 
Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias, IUOPA, 
University of Oviedo, Oviedo, Spain. 4Department of Biochemistry and Molecular Biology, University of Oviedo, 
Oviedo, Spain. 5IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. Correspondence and requests for 
materials should be addressed to J.M.G.-P. (email: juanagp.finba@gmail.com)
Received: 30 June 2017
Accepted: 24 November 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENtIFIC REPORtS |  (2017) 7:17785  | DOI:10.1038/s41598-017-18138-8
prognosis and/or treatment of developmental defects, viral infections and different cancers13,14. miR-196a has 
been found upregulated in numerous cancer types, and proven to have pro-oncogenic functions promoting cell 
proliferation, migration, invasion and radioresistance15–21. miR-196b upregulation has been described in oral, 
gastric, colorectal cancer, glioblastoma and leukemia22–25. However, some reports have also shown that the miR-
196 family members may act as tumor suppressors. Thus, miR-196a suppressed metastasis in melanoma and 
breast cancers25,26, and miR-196b down-regulation has been reported in different types of leukemia27–30. Even 
though the frequent dysregulation of miR-196 family in cancer indicates a close association with disease status, 
the clinical and biological significance and regulatory networks have been explored to a very limited extent.
This study is the first to investigate the pathobiological role and clinical relevance of miR-196b in HNSCC 
and the possible influence on the surrounding tumor microenvironment. This was accomplished by monitoring 
miRNA expression in HNSCC tissue specimens, HNSCC-derived cell lines and cancer-associated fibroblasts 
(CAFs) isolated from HNSCC patients. The present study also explored for the first time the role of miR-196b in 
early stages of HNSCC tumorigenesis and malignant transformation by analyzing miRNA expression in a large 
series of premalignant lesions, seeking possible correlations with the risk of progression to invasive carcinoma. 
In addition, the abundance and potential utility of miR-196a/b as minimally invasive biomarkers were assessed 
in saliva samples. In vitro functional analysis demonstrated that altered miR-196a/b expression causes pleiotropic 
effects in HNSCC and the surrounding microenvironment, thereby eliciting cell-specific responses in target genes 
and downstream regulatory pathways, with distinctive impact on cell proliferation, migration and invasion.
Results
Frequent dysregulation of miR-196b expression in HNSCC tissue specimens. miR-196 expres-
sion levels were analyzed using Taqman™ miRNA assays in 19 fresh HNSCC tissue specimens and 11 patient-
matched normal epithelia. miR-196b levels were found to significantly increase in 18 (95%) tumors (T) (range 4 
to 83-fold) and also in 3 (27%) patient-matched normal mucosa (NC) (range 7 to 15-fold), compared to non-on-
cologic patients (N) (Fig. 1). miR196a levels were also found to frequently increase in HNSCC tissue specimens, 
in accordance to previous reports14–16. Thus, increased miR-196a levels were detected in 100% of tumors (range 
3 to 159-fold) and also in 5 of 11 (45%) patient-matched normal epithelia (range 3 to 18-fold) (Supplementary 
Figure S1).
We next assessed potential associations between miR-196a and miR-196b expression and clinicopathologic 
characteristics (Supplementary Figure S2). However, no significant differences were observed when comparing 
miR-196a and miR-196b levels by tumor site (larynx versus pharynx), lymph node infiltration (pN classification, 
dichotomized as N0 versus N1–3), and disease stage (IV versus I–III).
Expression of miR-196b in early stages of HNSCC tumorigenesis. miR-196b expression was 
evaluated in formalin-fixed paraffin-embedded (FFPE) tissue samples from 40 patients with laryngeal dyspla-
sia, comprising 17 non-progressing and 23 progressing lesions. miRNA expression was also analyzed in the 23 
patient-matched invasive tumors subsequently developed and compared to that of the corresponding prema-
lignant lesion. Normal epithelium (FFPE) obtained from 5 non-oncologic patients without exposure to tobacco 
carcinogens was used as healthy control.
Quantitative analysis showed that significantly increased levels of miR-196b were detected in an overwhelm-
ingly high percentage of precancerous lesions (95%), compared to healthy controls (Fig. 2). These data docu-
mented the early occurrence and high prevalence of miR-196b dysregulation in HNSCC tumorigenesis; however, 
no significant differences were observed when comparing the expression levels in non-progressing versus pro-
gressing dysplasias and patient-matched tumors subsequently developed. Similar results were obtained from the 
analysis of miR196a levels using the same set of precancerous lesions (Supplementary Figure S3).
Detection of miR-196a and miR-196b expression in saliva samples from HNSCC patients. The 
frequent miR-196a/b dysregulation in HNSCC patients (95–100%) prompted us to investigate the abundance 
and potential utility of both miRNAs as minimally invasive biomarkers for the early diagnosis and/or monitoring 
Figure 1. Analysis of miR-196b expression in HNSCC tissue specimens. miR-196b expression levels were 
quantified by RT-qPCR in 19 fresh primary tumors (T) and patient-matched normal counterparts (NC). Data 
were normalized to RNU48 levels, and relative to the normal mucosa from non-oncologic patients (N).
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of disease status. miR-196a and miR-196b expression was successfully detected in all saliva samples tested (from 
15 HNSCC patients and 11 healthy controls). Furthermore, increased levels of both miRNAs were observed in 
saliva samples from HNSCC patients compared to healthy controls (Fig. 3), with trends almost reaching statistical 
significance.
In vitro functional role of miR-196a and miR-196b expression in HNSCC-derived cell lines and 
cancer-associated fibroblasts. There is a crosstalk between cancer cells and the surrounding stroma. miR-
NAs may play an important role as they can be secreted from tumor cells into exosomes, thereby modulating 
the tumor microenvironment acting as paracrine signaling factors. Consequently, the pathobiological role of 
altered expression of miR-196a and miR-196b in HNSCC was assessed in both HNSCC-derived cell lines and 
cancer-associated fibroblasts (CAFs), which are a major constituent of the tumor stroma. A series of functional 
studies were carried out using various in vitro cellular models (FaDu, UT-SCC-42B, and CAFs) transiently trans-
fected with specific pre-miR precursors to determine their impact on cell proliferation, migration and invasion. 
Transfection with pre-miR-196a and pre-miR-196b respectively led to a robust induction of mature miR-196a 
and miR-196b levels in HNSCC cells and CAFs, compared to the endogenous levels in control-transfected cells 
(Supplementary Figure S4). Although some cross-reactivity was seen between pre-miR precursors and mature 
miR-196a and miR-196b, specificity was >90% in all cases.
The functional consequences of miR-196a and miR-196b over-expression varied depending on the cell type. 
Thus, cell proliferation significantly increased in FaDu cells transfected with pre-miR196a or pre-miR196b com-
pared to control cells, whereas proliferation significantly decreased upon pre-miR transfection in UT-SCC-42B 
cells or remained unchanged in CAFs (Fig. 4A). Similarly, transfection with either pre-miR-196a or pre-miR-196b 
also significantly increased migration in FaDu cells, while transfection with pre-miR-196b specifically decreased 
cell migration in both UT-SCC-42B and CAFs (Fig. 4B and C). In addition, transfection with pre-miR-196b 
Figure 2. Analysis of miR-196b expression in early stages of HNSCC tumorigenesis. miR-196b expression 
levels were quantified by RT-qPCR in 40 patients with laryngeal precancerous lesions, comprising 17 non-
progressing dysplasias (NP), 23 progressing dysplasias (P) and the 23 patient-matched invasive tumors (T) 
subsequently developed. Normal epithelia from 5 non-oncologic patients were included as (N) healthy controls. 
***p < 0.001 by Holm-Sidak’s multiple comparisons test.
Figure 3. Analysis of miR-196a and miR-196b expression in saliva samples. (A) miR-196a and (B) miR-196b 
expression levels were quantified by RT-qPCR in saliva samples from 15 HNSCC patients and 11 healthy 
controls and normalized to RNU48 levels with p values calculated by Student t-test.
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specifically decreased cell invasion in CAFs, whereas it had no effect in the two HNSCC cell lines tested (Fig. 4D–
E). These data evidence that altered expression of miR-196a and miR-196b causes pleiotropic effects depending 
on specific cellular and tissue contexts.
Figure 4. Functional analysis of miR-196a and miR-196b in HNSCC-derived cell lines and CAFs. UT-SCC-
42B, FaDu cells and CAFs were transfected with either premiR-196a, premiR-196b or non-targeting control, 
as indicated. (A) Cell proliferation was estimated by Tetrazolium-based MTS assay after 4 days. Data were 
normalized to the absorbance at day 0 and relative to control-transfected cells. (B) Bar chart showing the 
relative migration of UT-SCC-42B, FaDu or CAFs transfected with premiR-196a, premiR-196b or non-targeting 
control. (C) Representative images from the wound healing assays showing the initial scratch (t = 0) area and 
the residual area at each established final time (5, 15 or 20 h for UT-SCC-42B, FaDu or CAFs, respectively). (D) 
Bar chart showing the relative invasion of UT-SCC-42B, FaDu or CAFs transfected with premiR-196a, premiR-
196b or non-targeting control. (E) Representative images from the 3D invasion assays of CAFs spheroids 
embedded into a collagen matrix. The invasive area was determined by calculating the difference between the 
final area (t = 20 h) and the initial area (t = 0) using Image J analysis program. All data were normalized to 
control-transfected cells and expressed as the mean ± SD of at least three independent experiments performed 
in quadruplicate. *p < 0.05, **p < 0.01 and ***p < 0.001 by Student t-test.
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Identification of endogenous target genes in HNSCC-derived cell lines and cancer-associated 
fibroblasts. The identification of putative miR-196a/b targets is of primary interest for deciphering their func-
tional roles. Therefore, gene expression regulation by pre-miR-196a and pre-miR-196b transfection was examined 
in both HNSCC cells and CAFs on a panel of validated and/or predicted miRNA target genes in HNSCC and 
other cancer types (reviewed in13,14, and miRTarBase, Tarbase and TargetScan). Results showed that the endog-
enous levels of various genes (ANXA1 and HOX family) were consistently and significantly down-regulated 
upon miR-196a and miR-196b over-expression in UT-SCC-42B, FaDu and CAFs (Fig. 5), in accordance with 
their proposed mediator role as direct target genes. FASLG expression levels were significantly down-regulated 
by miR-196a and miR-196b in FaDu cells and also by miR-196a in UT-SCC-42B cells, but undetectable in CAFs. 
Hence, this study provides the first experimental evidence to validate FASLG gene as a miR-196a/b target gene in 
HNSCC. In contrast, the expression of certain other genes (HMOX1, KRT5, NFKB1, S100A9, TNF) was found to 
be significantly and differentially upregulated depending on the cell type, suggesting indirect regulation by miR-
196a/b. We also observed several cell- and miRNA-specific changes, such as the downregulation of TNF and FAS 
expression by miR-196b in CAFs, or the downregulation of NFKB1 by miR-196b in FaDu cells. None of these 
genes have been previously demonstrated to be miR-196b target genes in HNSCC and CAFs.
Figure 5. Analysis of miR-196a and miR-196b target genes in HNSCC cells and CAFs. mRNA expression levels 
of potential/validated miR-196a/b target genes were measured by RT-qPCR in (A) UT-SCC-42B, (B) FaDu 
and (C) CAFs after 72 h transfection with either premiR-196a, premiR-196b or non-targeting control. Data 
were normalized to RPL19 levels and relative to control-transfected cells. The graphs represent the mean ± SD, 
calculated from at least three independent experiments performed in triplicate. ND, not detected. *p < 0.05, 
**p < 0.01 and ***p < 0.001 by Student t-test.
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Distinctive effects of miR-196a and miR-196b expression on the activation of signaling path-
ways in HNSCC-derived cell lines. The differential functional effects caused by miR-196a/b overexpres-
sion on UT-SCC-42B and FaDu cells were further investigated by analyzing the activation status of multiple 
intracellular signaling pathways, using a phosphokinase array. As shown in a heat map representation (Fig. 6A), 
miR-196a/b overexpression led to widespread changes in the phosphorylation levels of protein kinases. Increased 
phosphorylation was observed in FaDu cells, predominantly in JNK/c-Jun and p38 MAP kinases. This contrasted 
with an overall decrease in phosphorylation levels of various kinase cascades that regulate cell proliferation, as 
detected in UT-SCC-42B cells, such as JNK/c-Jun, p38 and MAPKs, PI3K/mTOR and STAT signaling pathways. 
The phosphorylation of certain sites was robustly and specifically induced in UT-SCC-42B cells by both miR-
196a/b: SRC (Tyr419), AKT (Ser473), and ERK1/2 (Thr202/Tyr204; Thr185/Tyr187), although it is unlikely this 
would contribute substantially to the reduced proliferation observed in this cell line. A robust induction of p27 
(Thr198) phosphorylation was also specifically detected in UT-SCC-42B, possibly involved in cell cycle control 
and regulation of cell growth.
The results obtained with the protein array were further validated by Western blot. Figure 6B–D confirms the 
cell-specific changes in phosphorylation detected in both HNSCC cell lines i.e. JNK (pT183/pY185) activation in 
FaDu cells, downregulation of phosphoAMPKα (Thr172) in UT-SCC-42B, and activation of pAKT (Ser473) and 
ERK (T185/Y187) in UT-SCC-42B cells.
Discussion
miRNAs have emerged as key regulators of gene expression and crucial players in health and disease8–10. The 
characterization of miRNA expression patterns in cancers has demonstrated utility in disease diagnosis, progno-
sis, and therapy31–34. The frequent dysregulation of miR-196 family members in numerous cancer types reflects 
a close relationship with disease status and potential as biomarkers13,14. Nevertheless, the clinical and biological 
significance and underlying regulatory networks have been explored only to a limited extent, a prerequisite before 
any clinical application can be safely introduced. Although most studies have demonstrated prooncogenic func-
tions of miR-196a/b in multiple cancer types15–21, there is contrary evidence of a tumor suppressive role22–24. The 
miR-196 family may have many different targets depending on the cellular and tissue context, and consequently, 
the ultimate impact on tumor pathogenesis will depend on the balance between oncogenes and tumor suppressor 
genes targeted by these miRNAs in specific cell types. This, in turn, is moderated by distinct promoter regulation 
for each of these miR-196′s and variant binding sites in their target genes.
Figure 6. Analysis of signaling pathways targeted by miR-196a and miR-196b. Total protein lysates from UT-
SCC-42B and FaDu cells transfected with either premiR-196a, premiR-196b or non-targeting control were 
applied to a proteome phospho-kinase array. (A) Relative signal intensity values (to control-transfected cells) 
are displayed as a heat map. (B) Western blot validation of the array data. (C) and (D) Quantification of IRDye 
fluorescent signals. *p < 0.05, **p < 0.01 and ***p < 0.001 by Student t-test.
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The tumor and the surrounding microenvironment affect each other through constant physical and chemi-
cal interactions and together exert a major influence on tumor progression and disease outcome. miRNAs can 
be secreted into exosomes thereby acting as paracrine signaling factors between cancer cells and the tumor 
microenvironment (TME)35,36. Taking this into consideration, we initiated this study on the expression and func-
tional role of miR-196b in both HNSCC and CAFs as a major component of tumor stroma. Interestingly, our 
study provides the first evidence for the functional and regulatory role of miR-196a/b in CAFs. Consequently, 
miR-196a/b may provide an important bidirectional communication between cancer cells and the surrounding 
CAFs. Nevertheless, miR-196 could also mediate paracrine communication with other TME components, such 
as immune or endothelial cells. Therefore, the functional impact of miR-196 may be even greater than herein 
described, which merits detailed investigation.
Quantitative analysis consistently showed increased levels of both miR-196a and miR-196b in an overwhelm-
ingly high percentage (95–100%) of HNSCC tissue specimens. Expression varied in levels and percentage, being 
higher for miR-196a than miR-196b both in magnitude and frequency. In addition, increased levels of both miR-
NAs were detected in a considerable proportion (27–45%) of patient-matched normal epithelia, suggesting the 
early occurrence of these molecular changes. This hypothesis was further substantiated by analyzing miRNA 
expression in the early stages of HNSCC tumorigenesis. Thus, miR-196a and miR-196b expression was found 
markedly increased in 95–100% laryngeal precancerous lesions, and expression levels were maintained or even 
augmented in the patient-matched invasive carcinomas subsequently developed. Our findings also revealed that 
miR-196a/b expression did not reliably predict the risk of progression to invasive carcinoma. Consequently, 
although miR-196a and miR-196b dysregulation appears to be characteristic of HNSCC pathogenesis, it does not 
seem to play a determinant role in malignant transformation. miR-196a/b dysregulation could instead be a con-
sequence of uncontrolled proliferation rather than a causative agent in tumor development and acquisition of the 
invasive phenotype. Similarly, miR-196a and miR-196b levels were not found to correlate significantly with the 
clinicopathologic characteristics of HNSCC patients, suggesting their application as tumor markers for diagnosis 
or disease monitoring rather than prognostic factors.
Since miRNAs are secreted into exosomes and stably released into the circulation, their detection in body 
fluids could provide novel non-invasive biomarkers for clinical application to replace or complement currently 
invasive biopsy approaches. Liquid biopsy has emerged as an alternate option to track disease changes in a simple, 
minimally invasive manner, allowing for serial sampling to inform about the tumor heterogeneity, response to 
treatment and/or minimal residual disease37. Saliva is an accessible biofluid surrounding HNSCC that can serve 
as a biomarker source with multiple advantages over blood sampling, such as easier and safer collection, handling 
and storage38. This study determined that increased levels of miR-196a/b can be detected in saliva samples from 
HNSCC patients, highlighting their potential utility as biomarkers for early HNSCC detection and/or disease 
surveillance in tissue samples and saliva. Similarly, elevated miR-196a/b levels have been detected in plasma from 
patients with digestive tract cancers14,39, thus broadening their clinical applicability as circulating tumor markers.
In vitro functional studies further characterized the pathobiological role of miR-196a/b dysregulation in both 
HNSCC-derived cell lines and CAFs. According to our results, miR-196a/b exhibit multifaceted roles in HNSCC 
and the surrounding tumor stroma. We found that both miR-196a and miR-196b contributed to cell proliferation 
and migration in tumor cells, although led to opposite effects depending on the HNSCC cell line tested (i.e. both 
pre-miR196a and miR196b consistently increased proliferation/migration in FaDu cells while decreased prolif-
eration/migration in UT-SCC-42B). Thus, miR-196a and miR-196b were both pro-oncogenic in FaDu and sup-
pressive in UT-SCC-42B cells. miR-196b also specifically inhibited the migratory and invasive potential of CAFs. 
These results clearly demonstrate that altered expression of miR-196a and miR-196b causes pleiotropic effects in 
HNSCC depending on specific cellular and tissue contexts.
The possible molecular mechanisms whereby miR-196a/b regulates cellular functions were investigated to 
identify potential gene targets and downstream regulatory pathways, including ANXA1 and HOX genes, com-
monly regulated by miR-196a/b. This study provided original experimental evidence for several novel genes tar-
geted by miR-196a/b in HNSCC cells, such as FASLG and NFKB1, or TNF and FAS specifically targeted by 
miR-196b in CAFs. Despite the single nucleotide difference between mature miR-196a and miR-196b, these two 
molecules have shown a wide range of expression and functional roles in different cancers. Thus, both miR-
196a/b targeted NME4 expression to induce cell migration and invasion in oral cancer15. miR-196a was found to 
enhance radioresistance in HNSCC cells by suppressing ANXA116. In gastric cancer, miR-196a regulated the cell 
cycle regulator p27kip1 to promote cell proliferation17. miR-196a also promoted cancer progression by targeting 
NFκB-Iα in pancreatic cancer19. In colorectal cancer, miR-196a inhibited the expression of HOXA7, HOXB8, 
HOXC8 and HOXD8 genes, leading to AKT pathway activation and increased cell motility40. Also in colorectal 
cancer, miR-196b repressed FAS expression modulating cell apoptosis24. miR-196a promoted cell proliferation 
and invasion mediated by HOXA5 in lung cancer21. miR-196a was also found to promote cell proliferation and 
migration by inhibiting p27kip1, FOXO1 or NTN4 in cervical cancer20,41. In marked contrast, miR-196a inhibited 
HOXC8 to reduce cell proliferation and invasion in melanoma26. miR-196 was also found to suppress cell invasion 
in breast cancer, although miR-196 expression levels did not correlate with clinical metastasis status27. In chronic 
myeloid leukemia, low miR-196b levels enhanced the activity of BCR-ABL1 and HOXA9 oncogenes28.
We also found that miR-196a/b caused widespread changes in the activation status of multiple intracellular 
signaling pathways in a cell-dependent manner. Noteworthy, the proteome arrays (Fig. 6A) showed consistent 
phosphorylation changes by miR196a and miR196b on FaDu cells, although dramatically different to those in 
UT-SCC-42B cells. These data suggest that the distinct cell/tissue specificity among the various regulatory targets 
of miR-196a/b and ultimately the dynamic balance between the oncogenes and tumor suppressors targeted deter-
mine cell fate. This reflects the complexity of the miRNA-target regulatory network and how a single miRNA may 
act as oncomir or antagomir depending on specific cell/tissue context. Due caution must be taken when planning 
to target a miRNA for cancer therapy.
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Together, these findings reveal the early occurrence and prevalence of miR-196b dysregulation in HNSCC 
tumorigenesis, suggesting its possible utility for early diagnosis and/or monitoring of disease status. Furthermore, 
the potential of mir-196a/b as non-invasive biomarkers in saliva was also considered. However, the pleiotropic 
effects caused by miR-196a/b in HNSCC and the surrounding microenvironment cast doubt on their possible 
application as therapeutic targets.
Methods
Patients and Tissue Specimens. Surgical tissue specimens (fresh frozen) from 19 patients with HNSCC 
who underwent resection of their tumors at the Hospital Universitario Central de Asturias between 2000 and 
2002 were collected, in accordance with approved institutional review board guidelines. All experimental proto-
cols were approved by the Institutional Ethics Committee of the Hospital Universitario Central de Asturias and by 
the Regional CEIC from Principado de Asturias (approval number: 70/16 for the project PI16/00280). Informed 
consent was obtained from all patients. All patients had a single primary tumor (in the larynx or pharynx), micro-
scopically clear surgical margins and received no treatment prior to surgery. The clinicopathologic characteristics 
of these patients are shown in Supplementary Table S1. Patient-matched normal adjacent epithelia were also 
collected from the same anatomical site (contralateral) in 11 out of 19 patients. In addition, normal epithelia from 
non-oncologic patients without exposure to tobacco carcinogens (i.e. childhood tonsillectomy) were collected 
and used as healthy controls.
Formalin-fixed paraffin-embedded (FFPE) tissue samples from 40 patients who were diagnosed of laryn-
geal dysplasia at the Hospital Universitario Central de Asturias and the Hospital Universitario Donostia were 
retrospectively collected, in accordance with approved institutional review board guidelines. The histological 
diagnosis was confirmed by an experienced pathologist. The clinical features of these patients are summarized 
in Supplementary Table S2. Tumor blocks were also obtained from those patients who developed an invasive 
carcinoma (23 cases). All patients were treated by excisional biopsy using stripping microflap excision with cold 
instruments. A complete macroscopic exeresis of the lesion was performed in all cases, but the microscopic mar-
gins were not addressed. Patients were followed-up for a minimum of 60 months or until progression to malig-
nancy occurred. FFPE normal epithelium from 5 patients was also collected and used as control.
Saliva samples were prospectively collected from 15 HNSCC patients (13 male and 2 female, age range 46–88 
years) before surgical treatment of their tumors at the Hospital Universitario Central de Asturias, in accordance 
with the Ethics Committee approval. All patients had a single primary tumor, microscopically clear surgical 
margins and received no treatment prior to surgery. Saliva samples from 11 healthy donors (8 male and 3 female, 
age range 26–71 years) were also collected. Saliva samples were collected following the procedure previously 
described42, and frozen at −80 °C until miRNA purification. The entire volume of saliva sample, without centrif-
ugation of cells, was used for miRNA purification.
miRNA expression analysis. Total RNA (including miRNA) was extracted from fresh frozen tissue and/
or cultured cells using Trizol (Invitrogen Life Technologies). miRNAs were isolated from FFPE tissue samples 
(both laryngeal precancerous lesions and patient-derived invasive tumors subsequently developed) using the 
RecoverAll kit from Ambion (Life Technologies, Paisley, UK), according to the manufacturer’s instructions. 
FFPE tissue sections from 40 laryngeal precancerous lesions (5–10 slides of 10 µm thickness) were selected to 
ensure >50% dysplastic cells. For patient-derived invasive tumors, two punches of 2 mm diameter were taken 
from representative areas of each FFPE tumor block using a new, sterile punch (Kai Europe GmbH, Solingen, 
Germany) to avoid cross-contamination. miRNAs from saliva samples were isolated using Nucleospin miRNA 
(Macharey Nagel). The relative levels of miR-196a and miR-196b were determined by two-step RT-PCR using 
miRNA-specific primers and probes according to the Taqman miRNA Assay protocol (Applied Biosystems) on 
a StepOnePlus Real-Time PCR System (Applied Biosystems). Reactions were run in triplicate, using RNU48 as 
control. The relative miRNA expression was calculated using the 2−ΔΔCT method and the data were normalized 
to RNU48 levels.
Analysis of miRNA targets by real-time RT-PCR. Total RNA was extracted using Trizol reagent and 
cDNA synthesized with Superscript II RT-PCR System (Invitrogen Life Technologies), according to manufactur-
er’s protocols. Gene expression was analyzed by Real-time PCR using the StepOnePlus Real-Time PCR System 
(Applied Biosystems) following Applied Biosystems’ SYBR Green Master Mix protocol, using the primers detailed 
in Supplementary Table S3. The constitutively expressed RPL19 ribosomal coding gene was used as endogenous 
control. The relative mRNA expression was calculated using the 2−ΔΔCT method and the data were expressed as 
the fold-change normalized to RPL19 mRNA levels and relative to control-transfected cells.
Cell Culture. FaDu cells (male, hypopharyngeal squamous cell carcinoma) were purchased to the American 
Type Culture Collection, and the HNSCC cell line UT-SCC-42B derived from a laryngeal squamous carcinoma 
(male, T4N3M0) was kindly provided by Dr. R. Grenman (Department of Otolaryngology, University Central 
Hospital, Turku, Finland)43. Cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS), 
100 U/ml penicillin, 200 mg/ml streptomycin, 2 mmol/l L-glutamine, 20 mmol/l HEPES (pH 7.3) and 100 mmol/l 
non-essential amino acids.
Cancer-associated fibroblasts (CAFs) were obtained from minced tumor tissue of surgically resected HNSCC 
(male, hypopharyngeal squamous cell carcinoma, T2N1M0) at the Hospital Universitario Central de Asturias. 
Briefly, fresh tumor samples from the operating theatre were cut into several small fragments, transferred to dry 
25 cm2 culture flasks and covered with a drop of complete culture medium (DMEM supplemented with 10% FBS, 
100 U/ml penicillin, 200 mg/ml streptomycin, 2 mmol/l L-glutamine, 20 mmol/l HEPES (pH 7.3) and 100 mmol/l 
non-essential amino acids) and incubated in 5% CO2 at 37 °C. Initial outgrowth of both tumor and fibroblast 
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cells was observed over 5–7 days, and fibroblasts were collected by repeated selective trypsinizations. Isolated 
CAFs were further characterized by Vimentin and α-SMA staining. All the cells used derived from HPV-negative 
primary tumors. Cell line authentication was performed by DNA (STR) profiling at the SCT Core Facilities 
(University of Oviedo, Asturias, Spain). All cell lines were tested periodically for mycoplasma contamination by 
PCR to specifically amplify a conserved region of the mycoplasma 16 S RNA gene (Biotools Detection kit).
Transfections with pre-miR miRNA precursors. Ambion Pre-miR miRNA Precursors AM17100 
hsa-miR-196a (#PM10068) and hsa-miR-196b (#PM12946) were purchased to Thermo Fisher Scientific and 
siGLO RISC-Free™ was used as non-targeting control (Thermo Scientific Dharmacon).
HNSCC cells and CAFs were seeded in 6-well plates at a density of 60,000 and 90,000 cells, respectively. The 
next day, cells were transfected with 100 nM of either pre-miR-196a or pre-miR-196b or a non-targeting control 
using Lipofectamine 2000 Transfection Reagent (Invitrogen Life Technologies), according to the manufacturer’s 
protocol. miRNA expression or mRNA gene expression was tested by real-time RT-PCR at 72 h post-transfection.
Proteome Array and Western blot Analysis. Proteins were extracted from HNSCC cells transfected with 
either pre-miR-196a, pre-miR-196b or a non-targeting control at 72 h post-transfection using lysis buffer (R&D 
Systems). 600 μg of each cell lysate was applied to the Proteome Profiler Human Phospho-Kinase Array (ARY003; 
R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. This is a membrane-based anti-
body array that allows simultaneous determination of the relative site-specific phosphorylation levels of 43 
human protein kinases. A cocktail of biotinylated detection antibodies, streptavidin–horseradish peroxidase and 
chemiluminescent detection reagents were used to detect the phosphorylated protein. Membranes were scanned 
with the Odyssey Fc Dual-Mode Imaging System (LI-COR Biosciences), and signal density analysis was per-
formed using Image Studio Lite software (LI-COR Biosciences).
Validation of specific phosphorylated proteins was carried out by Western blot analysis. Thus, protein lysates 
were resolved by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and transferred subsequently to nitrocel-
lulose membranes (Amersham Protran, GE Healthcare).
The membranes were blocked for 1 h with Odyssey blocking buffer and incubated overnight with the following 
specific primary antibodies at 1:1,000 dilution: JNK (pT183/pY185) (BD Biosciences #612540), phospho-Akt 
(Ser473) (Cell Signaling #9271), phospho-AMPKα (Thr172) (40H9) rabbit mAb (Cell Signaling #2535), ERK2 
(T185/Y187) Monoclonal Antibody (R&D Systems #MAB1825), and β-actin (dilution 1:10,000 for 1 h; Sigma 
Aldrich #AC15). The IRDye Infrared Fluorescent secondary antibodies Goat anti-Rabbit IRDye 800CW and Goat 
anti-Mouse IRDye 680RD were used for detection. Membranes were scanned with the Odyssey Fc Dual-Mode 
Imaging System (LI-COR Biosciences) using the red (700 nm) and green (800 nm) channels. Uncropped images 
of all the immunoblots can be found in Supplementary Information.
Cell proliferation assays. HNSCC cells and CAFs were respectively seeded into 96-well plates at a density 
of 1,500 and 3,000 cells per well, and cell proliferation was measured after 4 days. Quantification of cell number 
was determined in quadruplicates using a tetrazolium-based MTS test (CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay from Promega, Madison, WI) reading the absorbance at 490 nm with the use of a Synergy HT 
plate reader (BioTek, Winooski, VT).
Scratch-Induced Directional Migration Assay. Cells were plated in 24-well tissue culture dishes with ibidi® 
culture inserts (ibidi LLC, Verona, WI, USA) at 80–90% confluence. The following day, the culture inserts were 
detached to form a cell-free gap in the cell monolayer and the medium was changed to remove floating cellular debris. 
Migration was monitored using a Zeiss Cell Observer Live Imaging microscope (Zeiss, Thornwood, NY) coupled with 
a CO2 and temperature-maintenance system. Time-lapse images were acquired every 30 min during 24 h using a Zeiss 
AxioCam MRc camera. The area of each individual wound gap was measured in each culture condition using Image J 
image analysis program. Cell migration was analyzed by calculating the difference between the initial scratch area and 
the residual gap after 5, 15 or 20 h for UT-SCC-42B, FaDu or CAFs, respectively. For each culture condition, cell migra-
tion was quantified by comparing the area of the cell-free gap after normalization to the control cells.
Collective three-dimensional spheroid invasion assays. Cells were suspended in DMEM plus 
5% Methyl cellulose (Sigma) at 80,000 cells/ml medium to form cell spheroids (2,000 cells/spheroid) by serial 
pipetting of 25 μl into a non-adhesive Petri dish, and incubated in an inverted position for 18 h. Next day, each 
cell spheroid was transferred to an individual well of 96-well plate and embedded into bovine collagen matrix 
(Advanced Biomatrix PureCol), and filled with 100 μl of complete media. Collective cell invasion was moni-
tored using a Zeiss Cell Observer Live Imaging microscope (Zeiss, Thornwood, NY) coupled with a CO2 and 
temperature-maintenance system. Time-lapse images were acquired every 30 min during 20 h using a Zeiss 
AxioCam MRc camera. The invasive area was determined by calculating the difference between the final area 
(t = 20 h) and the initial area (t = 0) using image J analysis program, and data were normalized to the control cells.
Statistical Analysis. The data are presented as the mean ± standard deviation (SD) unless otherwise stated, 
and compared using one-way ANOVA or unpaired Student’s t-test. Statistical analysis was performed using 
GraphPad Prism version 6.0 (Graphpad Software Inc, La Jolla, CA, USA). p values less than 0.05 were considered 
statistically significant (p < 0.05, *p < 0.01, **p < 0.005, ***).
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